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THOMAS E. STARZL and ANTHONY J. DEMETRIS 
TRANSPLANTATION TOLERANCE, MICROCHIMERISM, AND 
THE TWO-WAY PARADIGM 
l. INTRODUCTION 
Melvin Cohn has extolled the virtues of immunologic hypotheses which 
accommodate all relevant observations as opposed to concise "small 
theories" that explain only a few facts.1 Exemplifying Cohn's argument, 
the inability to evolve an encompassing explanation for observations made 
in human and animal allograft recipients, or in surrogate in vitro models, 
has driven much of transplantation research down a reductionist pathway. 
Two premises that were introduced into transplantation immunology 
between 1944 and 1959 explain why. One was that the events following 
transplantation could be defined in terms of one-way immune reactions: 
host versus graft (HVG) and graft versus host (GYH). When this assump-
tion was combined with the second premise that whole organ allograft 
"acceptance" was fundamentally different from the chimerism-dependent 
acquired tolerance of Billingham, Brent, and Medawar2,3, a derivative 
dogma emerged that we have called "the one-way paradigm',.4 
2. THE Y IN THE ROAD: 1962 
Until 1959, the production of chimerism by donor leukocyte infusion in 
preparation for organ allotransplantation was a much anticipated natural 
extension5,6 of the neonatal tolerance models of Billingham, Brent, and 
Medawar2,3 and of the adult rodent analogues that required recipient 
cytoablation.7,8 In both the neonatal and cytoablation models, the trans-
planted leukocytes caused graft-versus-host disease (GVHO) unless there 
was close donor/recipient histocompatibility.9-11 
When long survival of functioning human kidney allografts was accom-
plished in sublethally irradiated recipients (1959-1962) without donor 
leukocyte injusion 12- 14 and then regularly (1962 onward) using contin-
uous pharmacologic immunosuppression and no cytoreduction, 15-1 H the 
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need in organ transplantation for both chimerism and recipient precondi-
tioning seemingly had been eliminated. These conclusions also defocused 
an understanding of bone marrow transplantatllon which was widely 
construed to be an example of total donor leukocyte chimerism: i.e. 
complete replacement of the immune system. 
Because there was little room for immune interactions (i.e. combined 
HVG and GVH responses) in the evolving framework of transplantation 
immunology, objections to the simplistic concept of a one-way reac-
tion were not taken seriously. In their alternative hypothesis, Simonsen, 19 
supported by Michie, Woodruff, and Zeiss,20 postulated in 1960-1961 that 
coexisting donor and recipient immune cells in neonatally tolerant mice 
had achieved a mutually nonreactive state while retaining the ability to 
function collaboratively (e.g. in a joint immune response to infection). 
Interest in this hypothesis evaporated when Simonsen recanted it in 1962,21 
largely because no experimental support could be found. 
In addition, however, nothing less than host clonal deletion to explain 
acquired transplanation tolerance appeared to be compatible with the 
consensus of that time. The disputes about clonal selection as the basis 
for self/non-self delineation seemingly had been brought to closure by the 
ultimate imprimatur of the Nobel Prize, which was awarded to MacFarland 
Burnet in 1960.22 ,23 It was no coincidence that the 1960 co-laureate with 
Burnet was Peter Brian Medawar, whose observations in the neonatal 
tolerance model2,3 were widely considered to be a validation of Burnet's 
prediction that developing lymphocytes with an open repertoire of recep-
tors could be purged of self-reactive cells before they achieved functional 
maturity. The tolerance produced in radiation chiimeras 7.8 was viewed as 
an iatrogenically engineered simulation of these events of ontogeny. 
The argument that clonal deletion is the key mechanism of either 
neonatal, cytoablation, or drug-induced tolerance has not been considered 
defensible by Schaffner,22.23 Cohn,l Nossal,24 and Tauber. 25 If it depended 
solely on clonal deletion, organ transplantation was difficult to envision as 
a biologically sound undertaking. In fact, Burnet did not. In 1961, he wrote 
in the New England Journal of Medicine that " ... much thought has been 
given to ways by which tissues or organs not genetically and antigenic ally 
identical with the patient might be made to survive and function in the 
alien environment. On the whole the present outlook is highly unfavorable 
to success .... ,,26 
TRANSPLANTATION, MICROCHIMERISM, AND TWO-WAY PARADIGM 443 
One-Way Paradigm (Organ) 
~ 
~"~K:K '0,,,, .:. ~ 
: ....... :.: 
~oo o 0 ~:D 
Deten •• LI ... Gr... ~" * 
HVG Eoeiectlon:~~~""DDDD-DDDKfIK· ..-, _i""'.'" 
Two-Way Paradigm (Organ) 
...-- GYM ----
I -'F"I!® I" 01:": :::~K: !,3J@" • ...... :.: .• ::lJ@ 010"":: ••• 
• ~ '-e .0'·. 0'0,,,. 
.. • • .:: 0 lg~· 
....::::"..... l ~@ , 
v ........... c.... u........... L c ............... c .............. ................... I 
HVG (Aejection,-I 
One-Way Paradigm (Bone Marrow) 
r::;-GVH 
I ~/: 
/
'"'' :::L: I~ 
II~D ctII .... '. ~4 :.; 
...................... 
--
ew--" ..... ...... 
'-.............. ..... 
Two-Way Paradigm (Bone Marrow) 
I GVH +; ~"D=i:=- ~":D •. !.' •1013: K:"~:K !", .. ;', ~ .e,,_ "j •••• : :::%l@ .. ~ :' .... tG '0 : !; .• : - .: .. ",: . 
..,.. ..::. ~ ::' . .: 
--~ 1'0· ". 
....... V ............... Ceh .... 0 .... t c,.......,. .... c ....... DIteMeM •• ........., ........... a.......... c .............. ·, ......... , 
Ioo-----HVG I 
Figure 1. (Upper panels) One-way paradigm in which transplantation is conceived as 
involving a unidirectional immune reaction: (left) host-versus-graft (HVG) with whole 
organs and (right) graft-versus-host (GVH) with bone marrow or other hematopoietic 
transplants. (Lower panels) Two-way paradigm in which transplantation is seen as a 
bidirectional and mutually cancelling immune reaction that is (left) predominantly HVG 
with whole organ grafts, and (right) predominantly GVH with bone marrow grafts, 
3. THE ONE-WAY PARADIGM 
3.1. Organ Transplanation 
With the widespread acceptance of the simplistic one-way paradigm that 
emerged from the 1959-1963 period, the unidirectional in vitro tests of 
immune reactivity 27,28 were automatically accepted as "minitransplant 
models", the results from which were assumed to be directly applica-
ble to in vivo circumstances of transplantation. An organ allograft was 
envisioned as a defenseless island in a hostile sea (Figure 1 upper left). 
With the opposite conditions of bone marrow transplantation, histoincom-
patible allografts rejected the defenseless recipient (GVHD) (Figure 1 
upper right). 
The one-way paradigm guided the strategies of recipient cytoablation 
and "immune system replacemenC7,8 that eventually led to successful clin-
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TABLE I 
Differences between conventional bone marrow and organ transplantation 
Bone marrow 
Yes 
Critical 
GVHD 
Common 
Tolerance 
+--- Recipient cytoablationa -+ 
+--- MHC compatibility -+ 
+--- Principal complication -+ 
+--- Drug free State -+ 
+--- Term for success 
Organ 
No 
Not critical 
Rejection 
Rare 
"Acceptance"b 
a Notes: All differences derive from this therapeutic step which in effect 
establishes an unopposed GVH reaction in the bone marrow recipient whose 
countervailing immune reaction is eliminated. 
b Or "operational tolerance". 
ical bone marrow transplantation in humans,29-33 a procedure that was 
(and is) feasible only with a perfect or good tissue (HLA) match. The 
belief that cytoablation (or cytoreduction) to "make microenvironmen-
tal space" was a prerequisite for leukocyte engraftment (reviewed in 34), 
became dogma in spite of early3S.36 and recent evidence34.37 that it was not 
true. 
To explain the differences between organ and bone marrow transplan-
tation (Table I), it was necessary to ascribe "graft acceptance" following 
the two kinds of procedures to disparate mechanisms. The assumption that 
chimerism, the sine qua non of bone marrow transplantation, was irrelevant 
to an explanation of successful organ transplantation lay at the root of the 
dilemma. 
4. THE TWO-WAY PARADIGM 
A connection between bone marrow and organ transplantation was made in 
1992 when donor leukocytes (microchimerism) were discovered up to 30 
years postoperatively in the peripheral tissues or blood of human recipi-
ents of kidneys, livers, and other organs 38-43 (Figure 1 lower left). The 
donor-derived cells were so few in number that sensitive immunocyto-
chemical and polymerase chain reaction (peR) techniques were required 
for their detection. However, we postulated that they were surviving leuko-
cytes from one limb of originally antagonistic but ultimately reciprocally 
attenuated or abrogated HVG (rejection) and GVH reactions (Figure 2). 
In the first few days after organ transplantation, multilinage bone 
marrow derived ("passenger") leukocytes constitute 1-20% of the host 
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Figure 2. Comtemporaneous host versus graft (HVG) and graft versus host (GVH) reac-
tions in the two-way paradigm as applied to organ transplantation. Following the initial 
interaction, the evolution of non-reactivity of each leukocyte population to the other is 
seen as a predominantly low-grade stimulatory state that may wax and wane, rather than 
one of absolute or irreversible clonal deletion. 
circulating mononuclear cells, depending on the kind of organ (i.e. highest 
with liver and intestine, lowest with heart or kidney).38,40.44 These leuko-
cytes, which include pluripotent stem cells45 .46 and dendritic cells38,4G-43 
migrate to the recipient lymphoid organs and are largely replaced in the 
graft by similar recipient cells.40,41.44.47-50 After about 2 weeks, small 
numbers of donor leukocytes can be found increasingly in other tissues 
and by 3 months they are mostly in non-lymphoid sites (e.g. skin and native 
heart).40.51.52 
Thus, even with the limited information available in 1992, it was 
possible to suggest that organ allograft acceptance involved " ... [acute] 
responses of co-existing donor and recipient immune cells, each to the 
other, causing reciprocal clonal expansion, followed by peripheral clonal 
deletion".38 Much evidence has accrued subsequently in support of this 
bidirectional mechanism (summarized in51 .52). 
A second mechanism also was proposed,38,40 namely that the depar-
ture from the transplanted organ of the donor leukocytes that drive the 
HVG response reduces the allograft's immunogenicity. This effect of 
leukocyte depletion has been demonstrated in many different experimental 
models.53- 58 For successful engraftment, the progressive change in organ 
immunogenicity and the clone-specific deletion of the recipient as well as 
donor leukocyte populations presumably take place in a close temporal 
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relationship. In time, a stable allograft emerging from this triple process 
may come to resemble an immunologically neglected infection.52 
5. PREVIOUS ENIGMAS 
5.1. Organ Transplantation 
The characteristic cycle of immunologic crisIs and resolution, first 
observed in drug immunosuppressed kidney recilpients and most practi-
cally monitored by serial changes in allograft function,16 was the product 
of a dual immune reaction (Figure 2). With the peripheral migration of 
the donor cells, and the influx of recipient cells 1Nhich do not cause graft 
damage when adequate immunosuppression is given, both the allograft and 
recipient become genetic composites (Figure 1 lower left). 
The mutually cancelling effect of the donor and recipient cell popu-
lations explains the rarity of GVHD following the engraftment in non-
cytoablated recipients of immunologically active organs such as the 
intestine and liver. Disruption of the leukocyte interaction with the host 
cytoablation used to prepare bone marrow recipients, but not the recipients 
of whole organs, obviously is responsible for the differences between the 
two kinds of procedure (Table I) including absolute dependence on HLA 
matching to avoid GVHD in the first instance but not the second. 
5.2. Bone Marrow Transplantation 
In the context of the two-way paradigm, it can be seen that bone marrow 
(Figure 3) and organ transplantation (Figure 2) are, in fact, mirror images, 
resulting from the drastically different treatment strategies4 (Table I). 
This conclusion has been supported by reports describing a trace residual 
population of recipient leukocytes in essentially all human bone marrow 
recipients who previously were thought to have complete donor cell 
chimerism (Figure 1 lower right). 59,60 
5.3. Post-Transplant Lymphoproliferative Disorders (PTLDs) 
The two-way paradigm casts new light on the B cell lymphomas (PTLD) 
that usually are of host origin in organ recipients and of donor origin after 
bone marrow transplantation. Ex.cept for their frequent Epstein-Barr virus 
(EBV) association, these human malignancies are indistinguishable from 
those induced by Robert Schwartz in a mouse chimerism model61 3 years 
before the PTLD complication was first recognized clinically.62 
Although these tumors correctly are explained in part by a loss of 
immune tumor surveillance,63 Schwartz attributed the development of 
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Figllre 3. The mirror image of Figure 2 after bone marrow transplantation to a recipient 
who has undergone cytoablation. 
similar neoplasms in his mouse model to the additional factor of a lympho-
proliferative response by the dominant immune apparatus against the 
persistent subclinical GVH and immunogenicity of the minority leukocyte 
population. The clinical relevance of Schwartz's observations, and of his 
"rules" of pathogenesis could not be appreciated until three decades later 
in the context of the two-way paradigm. 64 
6. THE "DEBATE" 
Non-vital antigen can also induce donor-specific non-reactivIty, albeit 
inefficiently and of limited duration, compared to live leukocytes. 3 In 
the chimerism-exclusionary context of the one-way paradigm, it became 
axiomatic that antigens of the parenchymal (or vascular endothelial) cells 
of transplanted organs induced allograft acceptance by ill-defined alterna-
tive mechanisms.65 In an extension of such reasoning, it has been argued 
that the microchimerism associated with successful transplantation, and 
conversely its disappearance with or just after irreversible rejection in 
experimental models,66-7o is epiphenomenal.71 
Skepticism about the significance of microchimerism (summarized 
in71 ,72) has been based on: (1) the inconsistency with which donor leuko-
cytes can be found in blood or tissue samples from organ recipients, (2) the 
development of acute or chronic rejection despite chimerism, and (3) the 
inability to use microchimerism to guide post-transplant drug weaning. All 
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of these ostensibly contradictory observations can be readily fitted into the 
concept of the various chimeric states, providing these states are consid-
ered along with the leukocyte depletion and altered immunogenicity of the 
allograft. Both of these factors vary with time, and according to antigen 
migration and localization. 52 
Starzl and Zinkernagel52 have proposed that the immunologic response 
or non-response against infections or tumors, and under the conditions 
of clinical transplantation, are governed primarily by the migration and 
localization of antigen. In their view, immune reactivity depends on migra-
tion of antigen to organized lymphoid tissue and can be viewed as " ... a 
balance between potentially reactive lymhocytes versus the qualities, quan-
tity, kinetics, and distribution of the antigen (foreign or self) within the 
host".52 
In this context, donor leukocyte chimerism is a prerequisite for, but 
neither synonymous with nor a consequence of, the evolution of allo-
graft tolerance.38,40,5I.52 Although the association of chimerism with organ 
allograft acceptance was discounted for a third of a century,S! the prin-
ciple of chimerism-linked organ allograft acceptance is no different than 
in the rodent neonatal,2.:l cytoablation-dependent,1,8 parabiosis-induced]] 
and more complicated "mixed chimerism" tolerance models74- 76 (Figure 
4). The theme came full-circle back to the observations by Owen 77 53 years 
ago of natural tolerance in freemartin cattle. 
7. MECHANISMS IN THE TWO-WAY PARADIGM 
The two-way paradigm defines success and failure after transplantation 
in a different way than before. Success implies that chimerism has been 
introduced which may or may not be immunosuppression-dependent. 
Treatment failure connotes the therapeutically uncontrollable ascendency 
of HVG or GVH.4,38,4o,n Pathologic evidence of both processes is found 
frequently in failed cases. Although the ultimate result almost always is 
predominantly one or the other, the two cell populations cross-modulate 
and are actively self-protective as a general rule. The reciprocal "defen-
sive" mechanism is particularly important if one cell population is out-
numbered and if there is severe major histocompatibility complex (MHC) 
dispartity. 
"T-cell tolerance" is an apposite term for donor-specific non-reactivity, 
but it is unlikely that allograft acceptance can be fully comprehended 
from the results of studies of individual leukocyte phenotypes.43 The 
totality of events leading to tolerance suggests learning (cognitive) func-
tions that have been explained by "networks".79-f:2 Network activity under 
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Figure 4. The continuum of chimerism from observations of Ray Owen in Freemartin 
cattle (77) to the present. Chimerism was incorrectly discounted as a factor in organ allo-
graft acceptance from about 1960 until the discovery in 1992 of microchimerism in organ 
recipients.38.40 
the circumstances of transplantation presumably would be multimechanis-
tically influenced by cytokines, immunoregulatory cells, antibodies, and 
other factors. 
Considering the shifting details of signalling and effector response 
involved in the merger of two interactive and genetically controlled 
immune systems, computer modelling based on known and experimen-
tally verifiable events may be required to fully comprehend the process. 
However, this level of information is not required to understand the seminal 
governance role of antigen migration and localization.52 
8. NON-TRANSPLANT ISSUES 
Transplantation does not involve unique immunologic responses. 52 For 
example, although the relation between infectious and transplantation 
immunity is complicated by the presence of a double immune reaction 
and the additional factor of therapeutic immunosuppression after trans-
plantation, the mechanisms and rules are basically the same and governed 
by antigen migration and localization. The two essential mechanisms 
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are antigen-driven clonal exhaustion/deletion, and "indifference" of the 
immune system to antigen that either does not reach lymphoid organs or 
survives passage through them.52 
Because the fetus possesses T cell immune function in the every early 
stages of its developmentIR1KoOKU~ it can be suggested that antigen migration 
and localization is the basis for the ontogeny of self/non-self discrimina-
tion in the same way as it is for acquired tolerance. Autoimmune diseases 
would then reflect unacceptable post-natal perturbations of the prenatally 
established lymphoid/non-lymphoid balance (self tolerance). Thus, we 
have suggested an extension and modification of the meaning of "immuno-
logic self,,52 which has been enigmatic since it was described a half century 
ago by FM Burnet.26 
9. CONCLUSION 
The assumption that hematolymphopoietic chimerism was irrelevant to 
successful whole organ transplantation as currently practiced led to alter-
native inadequate explanations of organ allograft acceptance, clouded 
the meaning of successful bone marrow transplantation, and precluded 
for more than three decades the development of a cardinal principle of 
transplantation. Recognition of this error and the incorporation of the 
chimerism factor into a two-way paradigm has allowed previous enigmas 
of organ as well as bone marrow engraftment to be explained and may 
allow a better understanding of immune function generally. 
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